GLP-1 TV · News & media
Coverage for GLP-1 denied after weight loss
Today’s cheapest GLP-1$41/mo at Wellmedr, sale price.Compare all GLP-1 prices Price read 16 Nov 2026 from the seller’s own page, ranked by price alone. That price is a compounded drug, and compounded drugs are not FDA-approved. Not from the video’s creator.Our summary
This report follows another speaker, a Sacramento Sheriff's Deputy who says Zepbound improved his sleep and energy and ended his sleep apnea. According to the video, he went from 250 lb to 170 lb. He says his appetite eased to the point where he stopped thinking about food all the time.
Published by NBC News on YouTube
As published by the channel. Not medical advice, and not an endorsement.
What else the video covers
When he went to renew his prescription, the video says his insurer, another speaker Health, denied coverage because his BMI was now under 30. The insurer had first covered Zepbound for sleep apnea. Another speaker says a BMI of 30 would put him around 200 lb, and he feels he is being pushed to gain weight to stay on the drug. Another speaker of the Medication Outcome Center at UC another speaker says insurers should treat GLP-1s like maintenance drugs, as they do blood pressure or cholesterol medications. She says cost and popularity have created a gray area in many plans, and that some plans raised the BMI threshold because of costs in the millions or tens of millions of dollars. Her advice is to be persistent.
Another speaker appealed and was denied again. Within weeks of the channel contacting another speaker Health, he was approved. Another speaker says the earlier denials came from an administrative submission error by his doctor, and that the first request was filed under the obstructive sleep apnea indication while the approved one used the weight management indication. Another speaker says no exception was made and the approval is not a universal policy. The report closes with a correspondent noting that studies conflict: some show weight regain after stopping, while three recent studies show as many as 70% of patients kept weight off for up to 2 years.
Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.
Takeaways
The main points, in the order they come up. Tap a time to play from there.
- 0:00 Another speaker says Zepbound ended his sleep apnea and helped him go from 250 lb to 170 lb.
- 0:31 His insurer, another speaker Health, denied renewal because his BMI had fallen under 30, according to the report.
- 1:02 Another speaker says insurers should treat GLP-1s as maintenance drugs, but cost has created a gray area in many health plans.
- 1:32 Another speaker advises persistence, and another speaker appealed after another denial.
- 2:02 Another speaker was approved within weeks of the channel contacting another speaker Health, which attributed the earlier denials to a submission error under the sleep apnea indication.
- 3:33 The report says three recent studies show as many as 70% of patients kept weight off for up to 2 years, while other studies show regain.
Key moments
Tap one to play from there.
What the video says
As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.
- Medication
- Zepbound
Questions this video answers
Why was GLP-1 coverage denied after weight loss?
In the video, another speaker's insurer, another speaker Health, told him his BMI was under 30 and the medication requires a BMI above 30. He had lost enough weight on Zepbound that he no longer met that threshold, according to the report.
Should insurers cover GLP-1 drugs as maintenance medication?
Another speaker of UC another speaker says insurers should treat GLP-1s like maintenance drugs, as they do blood pressure or cholesterol medications. She says the cost and popularity of the drugs have led to a gray area in many health plans.
Why was another speaker's Zepbound approved after denials?
Another speaker Health told the channel the earlier denials were an administrative submission error by his doctor. It says the first request was submitted under the obstructive sleep apnea indication, and the approved request was under the weight management indication.
Do people regain weight after stopping GLP-1 drugs?
The report says studies are mixed. Some show people gain weight back after stopping, while three recent studies show as many as 70% of patients kept the weight off for up to 2 years.
Videos on the same question
The closest videos in the library by what is said in them, not by title.
Got Questions About GLP-1s, Zepbound , Wegovy, Foundayo? DOWNSIZED LIVE!In this weekly live Q&A, the hosts of the channel say they are not doctors.
Shaquielle O'Neal Just Confirmed He's on Zepbound!This weekly news episode from the hosts of the channel covers eight GLP-1 stories.
GLP-1 agonists and the willpower mythThe speaker, the channel's host, describes a conversation he had the day before with a patient about starting a GLP-1 agonist.
GLP-1 / Zepbound / Tirzepatide Journey | 6 Month update, the good and the bad!The speaker, who says he is 32, marks six months on a GLP-1 medication that he started on November 3, 2025.
CoreAge Rx Reviews: Vanessa's GLP-1 Journey & the Community That Shows UpShe works in a primary care office and says she has seen specialists ask for patients to be started on GLP-1s for conditions such as sleep apnea and joint pain, which made her wonder whether it would work for her.
Read next
Our guides closest to what this video covers, with prices checked weekly.
- How to get a GLP-1 covered by insurance, in the order it actually works
There are four gates and most people fight the wrong one first. Before any clinical criterion applies, your employer has to have bought the weight-loss drug category at all, and if they did not, no BMI number and no comorbidity will change the answer. Once past that, the published criteria across the major insurers are strikingly consistent: BMI of 30 or more, or 27 with a weight-related condition, plus a documented period of lifestyle change, plus roughly 5 percent weight loss to stay approved at renewal.
- Zepbound for sleep apnea: what the label approves, what SURMOUNT-OSA found, and who pays for it
Zepbound is the only GLP-1 approved to treat moderate to severe obstructive sleep apnea, in adults with obesity, alongside diet and exercise. In the two 52-week SURMOUNT-OSA trials, breathing interruptions fell by about 25 to 29 events an hour on Zepbound against about 5 on placebo. The label's OSA maintenance dose is 10 mg or 15 mg a week. Because sleep apnea is a medical indication, Medicare's GLP-1 Bridge excludes it and points people to their Part D plan, which may cover it.
- Does your employer cover GLP-1s for weight loss? The 2026 numbers, who dropped it, and what to do
About one large employer in five covers GLP-1s for weight loss: 19% of firms with 200 or more workers in KFF's 2025 survey, rising to 43% of firms with 5,000 or more. Among the very largest employers coverage is now falling, from 72% in 2025 to 60% in 2026 in Business Group on Health's survey, and Cigna, PwC, HCA and several state plans have dropped it. Here is who covers it, the usual conditions, and how to check your own plan.
Next steps
Zepbound prices
Find more like it
Cost and insuranceStopping and maintenanceThe trials
Up next
More from this collection
Watched it? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.




















